Early Lapatinib-Induced Skin Rash Predicts Better Survival With Lapatinib+Trastuzumab Therapy - Cancer Therapy Advisor

Early development of skin rash following lapatinib and trastuzumab therapy is associated with improved survival.

Lapatinib and lapatinib plus trastuzumab therapy versus

Great Strides in Precision Medicine: Personalized Oncology

Page 1526 – Cancer Therapy Advisor

Lapatinib and lapatinib plus trastuzumab therapy versus

Cancer Therapy Advisor July/August 2016 Issue by Haymarket Media

Lapatinib and lapatinib plus trastuzumab therapy versus

Lapatinib: An Oral Dual Tyrosine Kinase Inhibitor for HER-2

Lapatinib and lapatinib plus trastuzumab therapy versus

Resistance and Overcoming Resistance in Breast Cancer - Oncology

Frontiers Dermatologic Toxicities of Targeted Therapy and

Cutaneous toxicities from targeted therapies used in oncology

January 2011 - Oncology Practice Digital Network